Movement disorders are neurological diseases and syndromes affecting the ability to generate and control movement. This disorder mainly affects brain, spinal cord and nerves throughout the body giving rise to cerebrovascular diseases, degenerative diseases of adult life, trauma, neuro-genetic diseases, developmental disorders, metabolic diseases, convulsive disorders, infectious diseases and brain tumors. According to World Health Organization (WHO), in year 2012, the U.S. health department recorded 6 million patients suffering from various movement disorders. The movement disorders that have high prevalence rate are Parkinson’s disease, dystonia, essential tremor, Huntington ’s disease, multiple system atrophy (MSA) among others. These diseases are initially diagnosed by collecting information about family history of patients, history of disease symptoms, neurological examination and other diagnostic tests such as blood test and imaging. Blood tests include complete blood count (CBC), creatine kinase test, DNA analysis (to determine if the disorder is genetic) and cerebrospinal fluid (CSF) analysis. Imaging tests that are used to diagnose movement disorders are computed tomography (CT scan), magnetic resonance imaging (MRI scan), and positron emission tomography (PET scan). In some cases to monitor electrical activity within the body for diagnosis of muscle and nerve disorders electromyogram (EMG) and electroencephalogram (EEG) are applied. Muscle biopsy was also observed to be one of the major diagnostic procedures that helps to differentiate between muscle and nerve disorder. In this procedure a sample of muscle is removed post local anesthesia for microscopic evaluation. Thus, diagnostics segment is driven by high prevalence rate of neurological diseases and increasing social awareness about these disorders.
The treatment for movement disorders is dependent on the type of movement disease. The first line of treatment mainly consists of anticonvulsants (such as carbamazepine or divalproex sodium), beta-blockers (propranolol), dopamine agonists (bromocriptine or pergolide) and tranquilizers (diazepam or clonazepam). In some cases the antipsychotics such as risperidone, olanzapine, quetiapine, chlorpromazine or haloperidol are used to suppress involuntary muscle activity. In Parkinson’s disease Levodopa, selegiline and amantadine are commonly used in Parkinson\'s disease to improve dopamine balance and reduce symptoms. In Huntington disease monoamine-depleting agents (monoamines are brain chemicals), such as reserpine, trihexyphenidyl or benztropine mesylate are applied. Botulinum toxin a neurotoxin is used in case of spasmodic torticollis, blepharospasm, myoclonus, and tremors to release muscle contraction causing neurotransmission. Deep Brain Stimulation (DBS) device is an implantable battery-operated medcial device used to deliver electrical stimulation to areas of the brain that control movement. Ablative surgery is one of the surgical processes that produce chemical or electrical impulses that cause abnormal movements where a heated probe or electrode is inserted into the targeted area to destroy certain tissues. The other ablation surgeries used to treat movement disorders are pallidotomy used to eliminate uncontrolled dyskinesia and thalamotomy applied to eliminate tremor.
North America was observed to be the largest market for movement disorder diagnosis and treatment. This dominance was mainly due to high prevalence of the disorder, technological advancements and high awareness among the patient population. Europe was observed to be the second largest market and one of the leading research destinations for neurological disease diagnosis and treatment. Asia-Pacific and Rest of the World were observed to be the most potential markets for movement disorders diagnosis and treatment market. These regions lack in advanced infrastructure and disease awareness. The future growth in these geographical regions is expected due to the presence of emerging economies such as China, India, Brazil and other countries that primarily prefer healthcare sector for developmental investment.
Some of the key players involved in the movement disorder market are Abbott Laboratories,Inc., Baxter International, Inc., Cardinal Health, Boston Scientific Corporation, Forest Laboratories, Hospira, Inc., F. Hoffmann-La Roche AG, Medtronic, Inc. Merck Serono, Mylan Pharmaceuticals, Neuroptix Corporation, Pfizer, Inc. and Torrent Pharma.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.